Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age≥ 18 years
Cohort A: Patients undergoing intensive induction chemotherapy for acute myeloid leukemia (AML; newly diagnosed or relapsed/refractory).
\* Any intensive regimen with planned \~4 weeks of inpatient stay
Cohort B: Allo-HCT patients
\* Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo
Voluntary written consent signed before performance of any study-related procedure not part of normal medical care
You may not be if
Planned continuation of antibacterial antibiotics after the first neutrophil recovery (ANC \> 1,000)
Patients who are currently receiving or recently received (within 28 days) other investigational agents.
Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Clareo Health | A Study of FMT in Patients With AML Allo HSCT in Recipients
